CoChat

PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers

Open access
Koychev, Ivan, on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, Roger N., Firouzian, Azadeh, Lawson, Jennifer, Zamboni, Giovanna, Ridha, Basil, Sahakian, Barbara J., Rowe, James B., Thomas, Alan, Rochester, Lynn, Ffytche, Dominic, Howard, Robert, Zetterberg, Henrik, MacKay, Clare, Lovestone, Simon · 2017 · Journal of Alzheimer's Disease
Cited by 69

The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Combining PET amyloid-β (Aβ) and tau imaging may be critical for tracking disease progression in Alzheimer's disease (AD). OBJECTIVE: We sought to characterize the relationship between Aβ and tau ligands as well as with other measures of pathology. METHODS: We conducted a multi-center observational study in early AD (MMSE >20) participants aged 50 to 85 y. The schedule included cognitive assessments (ADAS-Cog) and CSF measurement of Aβ and tau at baseline and 6 months; PET-CT imaging with Aβ ([18F]AV45) and tau ([18F]AV1451) ligands at baseline. RESULTS: 22 participants took part in the study with 20 completing its 6-month duration and 12 having both tau and amyloid PET. The PET biomarker analysis revealed a strong negative correlation between age and tau in multiple regions. Entorhinal cortex tau and age interacted significantly in terms of cognitive change over 6 months which may have been to older participants deteriorating faster despite lower levels of cortical tau. Cortical Aβ associated with entorhinal cortex tau while CSF tau/Aβ ratio correlated strongly with cortical tau but not Aβ. CONCLUSION: The negative relationship between age and cortical tau whereby younger patients with mild AD had relatively greater tau burden is potentially important. It suggests that younger-age onset AD may be primarily driven by tau pathology while AD developing later may depend on a multitude of pathological mechanisms. These data also suggest that PET-tau performs better than PET-amyloid in predicting the best validated AD diagnostic marker- the CSF total tau/Aβ ratio.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3233/jad-170129

Cites

24 of 24 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 24 references

Cited by

See all 69

Metadata

Authors
Koychev, I., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B., Sahakian, B. J., Rowe, J. B., Thomas, A., Rochester, L., Ffytche, D., Howard, R., Zetterberg, H., MacKay, C., & Lovestone, S.
Venue
Journal of Alzheimer's Disease
Published
2017-08-29
Volume
60
Issue
1
Pages
283-293
ISSN
  • 1387-2877 (ISSN-L)
  • 1875-8908
OpenAlex
W2744157997
Cited by
69
References
24
FWCI
6.38
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. https://app.cochat.ai/papers/10.3233/jad-170129
The paper
Koychev, I., on behalf of the Deep and Frequent Phenotyping study team (http://www.dementiastudy.co.uk/), Gunn, R. N., Firouzian, A., Lawson, J., Zamboni, G., Ridha, B., Sahakian, B. J., Rowe, J. B., Thomas, A., Rochester, L., Ffytche, D., Howard, R., Zetterberg, H., MacKay, C., & Lovestone, S. (2017). PET Tau and Amyloid-β Burden in Mild Alzheimer’s Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease. https://doi.org/10.3233/jad-170129

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.